Home / Countries / United Kingdom

WHO European Region · country profile

HIV, PrEP and sexual health access in the United Kingdom

The United Kingdom: 89% of verified HIV medicine records are reimbursed; PrEP is available and reimbursed; sexuality education is classified as progressive. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 02/11/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

Read more: HIV medicines in The United KingdomPrEP in The United KingdomDoxyPEP in The United KingdomSexuality education in The United KingdomAbortion and contraception rules in The United KingdomHealthcare for migrants in The United Kingdom

HIV medicines89% reimbursed25 of 28 verified recordsPrEPReimbursed111,123 PrEP recipients (England, 2024; UKHSA)DoxyPEPReimbursedNational access and guidanceSexuality educationProgressivePolicy frameworkFamily planning & abortionProgressiveAbortion law and contraceptionMigrant healthcare accessWarningEntitlement and practice

10 HIV medicine records for the United Kingdom are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in the United Kingdom?

Of 28 verified HIV medicine records for the United Kingdom, 25 are available and reimbursed (89%), 1 are available but not reimbursed and 2 are not available. 10 further records are still under review.

Reimbursed 25

Apretude, Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Generic TDF/FTC (Emtricitabine/Tenofovir DF), Genvoya, Intelence, Isentress, Juluca, Kaletra, Odefsey and 11 more

Available, not reimbursed 1

Yeytuo

Not available 2

Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz)

See every medicine with its source ↓

Is PrEP available and reimbursed in the United Kingdom?

Yes. In SHAPE's review, PrEP is available and reimbursed in the United Kingdom.

PrEP recipients: 111,123 PrEP recipients (England, 2024; UKHSA)

PrEP is provided through publicly funded health services; delivery arrangements differ among the four UK nations. England reported 111,123 people accessing PrEP in 2024. [Source: https://www.gov.uk/government/statistics/hiv-annual-data/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2025-report] Lenacapavir for PrEP (Yeytuo) was approved by the MHRA in December 2025, but NICE draft guidance of 9 September 2026 does not recommend it for use in NHS England on cost-effectiveness grounds; the consultation closes on 30 September 2026 and the next committee meeting is scheduled for 3 November 2026. Injectable cabotegravir PrEP was recommended by NICE in October 2025 with a restricted indication for people who cannot use oral PrEP effectively. [Source: https://www.nice.org.uk/guidance/indevelopment/gid-ta11638]

Is DoxyPEP available in the United Kingdom?

Yes. In SHAPE's review, DoxyPEP is available and reimbursed in the United Kingdom.

England's sexual health services began targeted DoxyPEP provision in 2025 for eligible gay, bisexual and other men who have sex with men and transgender women; arrangements elsewhere in the UK may differ. [Source: https://www.gov.uk/government/publications/doxypep-monitoring-and-evaluation]

What is the policy on sexuality education in the United Kingdom?

SHAPE classifies the sexuality education framework in the United Kingdom as progressive. This describes the national policy framework, not how every school delivers it.

  • National framework: Education policy is devolved. England has statutory Relationships, Sex and Health Education; Scotland, Wales and Northern Ireland use separate statutory or curricular frameworks with different content and opt-out rules.
  • Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.gov.uk/government/publications/relationships-education-relationships-and-sex-education-rse-and-health-education/relationships-and-sex-education-rse-secondary ; https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in the United Kingdom?

SHAPE classifies family planning and abortion rights in the United Kingdom as progressive, combining abortion law and contraception policy.

  • Abortion: In Great Britain, abortion is available up to 24 weeks under statutory grounds and provider authorization. Northern Ireland permits abortion on request through 12 weeks and on specified grounds later.
  • Contraception: EPF's 2026 contraception-policy score is 95.8%; the atlas records broad national coverage.
  • Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/countries/ ; https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_2026_FEB22-HiRes.pdf]

Can migrants access healthcare in the United Kingdom?

SHAPE's editorial comparison places migrant healthcare access in the United Kingdom in the middle category (Warning). Entitlement: Residence-based secondary care; free primary and specified public-health care.

Provider type: NHS / public health services / NGO · International migrants (2024): 11,845,479

  • Access rule: Primary care registration and specified public-health services are available without ordinary-residence status; HIV diagnosis and treatment are free, while many hospital services are residence based and chargeable.
  • Main barriers: Charging rules, proof requests, fear of data use, language and uncertainty about exemptions can delay secondary care.
  • Migration measure: UN DESA estimates 11,845,479 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
  • Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
  • Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
  • Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: India (8.8%), Poland (7.6%), Romania (6%)

Selected HIV indicators: Foreign-born HIV Diagnoses (known origin, 2024): 82.1%; Late HIV Diagnosis (CD4 <350, 2024): 47.5%

How the United Kingdom compares

The United Kingdom ranks #7 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (89%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

All HIV medicines in the United Kingdom

MedicineActive ingredientClassStatusEvidence and sourceChecked
Apretude
ViiV Healthcare
Cabotegravir (PrEP)INSTI (Long-Acting PrEP)ReimbursedRecommended by NICE in October 2025 for HIV pre-exposure prophylaxis with a restricted indication, limited to people who cannot use oral PrEP effectively (estimated at approximately 1,000 people per year). Provided through NHS specialised sexual health services. [Source: NICE / NHS England]02/11/2026
Biktarvy
Gilead Sciences
Bictegravir / Emtricitabine / TAFINSTI + NRTI/NtRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Celsentri
ViiV Healthcare
MaravirocEntry InhibitorReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Delstrigo
Merck
Doravirine / Lamivudine / Tenofovir DFNNRTI + NRTI/NtRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Descovy
Gilead Sciences
Emtricitabine / TAFNRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Dovato
ViiV Healthcare
Dolutegravir / LamivudineINSTI + NRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Edurant
Janssen
RilpivirineNNRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Generic TDF/FTC (Emtricitabine/Tenofovir DF)
Multiple (Generics)
Emtricitabine / Tenofovir DFNRTIReimbursedFully financed through the national health insurance framework. [Source: NHS / UKHSA]14/09/2026
Genvoya
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / TAFINSTI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Intelence
Janssen
EtravirineNNRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Isentress
Merck
RaltegravirINSTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Juluca
ViiV Healthcare
Dolutegravir / RilpivirineINSTI + NNRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Kaletra
AbbVie
Lopinavir / RitonavirPIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Odefsey
Gilead Sciences
Rilpivirine / Emtricitabine / TAFNNRTI + NRTI/NtRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Pifeltro
Merck
DoravirineNNRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Prezista
Janssen
DarunavirPIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Rekambys
Janssen
RilpivirineLong-Acting NNRTIReimbursedLong-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing United Kingdom record for the complete Vocabria / Rekambys regimen is classified as 'Available and Reimbursed', so this required rilpivirine component uses the same access and reimbursement status. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys]14/09/2026
Rukobia
ViiV Healthcare
FostemsavirAttachment InhibitorReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Sunlenca
Gilead Sciences
LenacapavirCapsid InhibitorReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Symtuza
Janssen
Darunavir / Cobicistat / Emtricitabine / TAFPI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Tivicay
ViiV Healthcare
DolutegravirINSTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Triumeq
ViiV Healthcare
Dolutegravir / Abacavir / LamivudineINSTI + NRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Truvada
Gilead Sciences
Emtricitabine / Tenofovir DFNRTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Vocabria
ViiV Healthcare
CabotegravirINSTIReimbursedProvided free of charge exclusively through NHS specialized sexual health clinics and hospitals. [Source: NHS / UKHSA]14/09/2026
Vocabria / Rekambys
ViiV Healthcare / Janssen
Cabotegravir / RilpivirineLong-Acting ARTReimbursedEMA approved. Fully or partially reimbursed under the national health system for virologically suppressed patients. [Source: NHS / UKHSA]02/11/2026
Yeytuo
Gilead Sciences
Lenacapavir (PrEP)Capsid Inhibitor (Long-Acting PrEP)Available, not reimbursedApproved by the MHRA in December 2025. NICE draft guidance of 9 September 2026 does not recommend lenacapavir for HIV prevention in NHS England on cost-effectiveness grounds, so it is not currently available on the NHS; the consultation closes on 30 September 2026 and the next committee meeting is scheduled for 3 November 2026. [Source: https://www.nice.org.uk/guidance/indevelopment/gid-ta11638]14/09/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir)
Multiple (Generics)
Tenofovir DF / Lamivudine / DolutegravirINSTI + NRTI/NtRTINot availableGeneric combinations are typically not procured as branded single-tablet regimens are widely available. [Source: NHS / UKHSA]14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz)
Multiple (Generics)
Tenofovir DF / Lamivudine / EfavirenzNNRTI + NRTI/NtRTINot availableGeneric combinations are typically not procured as branded single-tablet regimens are widely available. [Source: NHS / UKHSA]14/09/2026
Emtriva
Gilead Sciences
EmtricitabineNRTIUnder reviewEmtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva]14/09/2026
Epivir
ViiV Healthcare
LamivudineNRTIUnder reviewLamivudine is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/epivir]14/09/2026
Eviplera
Gilead Sciences
Rilpivirine / Emtricitabine / Tenofovir DFNNRTI + NRTI/NtRTIUnder reviewA once-daily fixed-dose HIV-1 regimen containing rilpivirine, emtricitabine and tenofovir disoproxil; resistance history and viral-load restrictions apply. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera]14/09/2026
Kivexa
ViiV Healthcare
Abacavir / LamivudineNRTIUnder reviewA fixed-dose NRTI backbone containing abacavir and lamivudine; HLA-B*5701 screening is required before abacavir treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa]14/09/2026
Norvir
AbbVie
RitonavirPI + pharmacokinetic enhancerUnder reviewRitonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir]14/09/2026
Retrovir
ViiV Healthcare
ZidovudineNRTIUnder reviewZidovudine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines; it is now generally a specialised or alternative treatment option. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir]14/09/2026
Rezolsta
Janssen
Darunavir / CobicistatPI + pharmacokinetic enhancerUnder reviewA fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta]14/09/2026
Stribild
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DFINSTI + NRTI/NtRTI + pharmacokinetic enhancerUnder reviewA once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild]14/09/2026
Viread
Gilead Sciences
Tenofovir DFNtRTIUnder reviewTenofovir disoproxil is a nucleotide reverse transcriptase inhibitor used with other antiretrovirals for HIV-1 treatment; renal and bone monitoring may be relevant. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/viread]14/09/2026
Ziagen
ViiV Healthcare
AbacavirNRTIUnder reviewAbacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy; HLA-B*5701 screening is required before treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in United Kingdom. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen]14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

  • gov.uk https://www.gov.uk/government/statistics/hiv-annual-data/hiv-testing…
  • nice.org.uk https://www.nice.org.uk/guidance/indevelopment/gid-ta11638
  • gov.uk https://www.gov.uk/government/publications/doxypep-monitoring-and-ev…
  • gov.uk https://www.gov.uk/government/publications/relationships-education-r…
  • unesco.org https://www.unesco.org/gem-report/en/peer
  • who.int https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexua…
  • bzga-whocc.de https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFE…
  • abortion-policies.srhr.org https://abortion-policies.srhr.org/countries/
  • epfweb.org https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_20…
  • who.int https://www.who.int/europe/health-topics/refugee-and-migrant-health
  • ecdc.europa.eu https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance…
  • gov.uk https://www.gov.uk/guidance/nhs-entitlements-migrant-health-guide
  • gov.uk https://www.gov.uk/guidance/hiv-migrant-health-guide
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/epivir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/norvir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/stribild
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/viread
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen

Explore more

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.